Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia The Case for Community Equipoise by Stone, Gregg W. et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 7 , N O . 1 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 9 . 0 5 6THE PRESENT AND FUTURE
STATE-OF-THE-ART REVIEWMedical Therapy With Versus Without
Revascularization in Stable Patients
With Moderate and Severe Ischemia
The Case for Community EquipoiseGregg W. Stone, MD,* Judith S. Hochman, MD,y David O. Williams, MD,z William E. Boden, MD,x
T. Bruce Ferguson, JR, MD,k Robert A. Harrington, MD,{ David J. Maron, MD{ABSTRACTFro
Re
ve
ch
Alb
No
tria
do
As
Ar
no
Sto
Ma
Am
Vid
Sm
an
rel
MaAll patients with stable ischemic heart disease (SIHD) should be managed with guideline-directed medical therapy
(GDMT), which reduces progression of atherosclerosis and prevents coronary thrombosis. Revascularization is also
indicated in patients with SIHD and progressive or refractory symptoms, despite medical management. Whether a
strategy of routine revascularization (with percutaneous coronary intervention or coronary artery bypass graft surgery
as appropriate) plus GDMT reduces rates of death or myocardial infarction, or improves quality of life compared to
an initial approach of GDMT alone in patients with substantial ischemia is uncertain. Opinions run strongly on both
sides, and evidence may be used to support either approach. Careful review of the data demonstrates the limitations
of our current knowledge, resulting in a state of community equipoise. The ongoing ISCHEMIA trial (International
Study of Comparative Health Effectiveness With Medical and Invasive Approaches) is being performed to determine
the optimal approach to managing patients with SIHD, moderate-to-severe ischemia, and symptoms that can be
controlled medically. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches
[ISCHEMIA]; NCT01471522) (J Am Coll Cardiol 2016;67:81–99) © 2016 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
BMS = bare-metal stent(s)
CABG = coronary artery
bypass graft
CAD = coronary artery disease
CCTA = coronary computed
tomographic angiography
CI = conﬁdence interval
DES = drug-eluting stent(s)
FFR = fractional ﬂow reserve
GDMT = guideline-directed
medical therapy
HR = hazard ratio
LVEF = left ventricular ejection
fraction
MACE = major adverse cardiac
events
MI = myocardial infarction
MT = medical therapy
OMT = optimal medical therapy
OR = odds ratio
PCI = percutaneous coronary
intervention
QALY = quality-adjusted
life-year
QoL = quality of life
RR = risk ratio
SIHD = stable ischemic
heart disease
SPECT = single-photon
emission computed
tomography
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82P atients with obstructive atheroscle-rotic coronary artery disease (CAD)may be asymptomatic (with or with-
out ischemia), or present with symptoms
ranging from stable angina, to acute coronary
syndromes (ACS) (unstable angina, non–
ST-segment elevation myocardial infarction,
or ST-segment elevation myocardial infarc-
tion), to sudden cardiac death. All patients
with established CAD should be prescribed
guideline-directed medical therapy (GDMT)
to mitigate progression of atherosclerosis
and to prevent myocardial infarction (MI)
and cardiovascular death (1,2). In patients
with biomarker-positive ACS, it is widely
accepted that routine revascularization, in
addition to GDMT, reduces the short- and
long-term rates of death and MI compared
with a more conservative approach (3–5). By
contrast, the extent to which routine revas-
cularization reduces death or MI, or improves
quality of life (QoL) in patients with stable
ischemic heart disease (SIHD) represents
one of the greatest uncertainties in contem-
porary cardiology. Given that an estimated
15.5 million Americans have CAD, and that
revascularization is performed in more than
1.3 million patients per year in the United
States alone (6), the appropriate (but judi-
cious) application of revascularization has
enormous implications for the medical and
economic health of the nation and the global
community.
Early randomized trials of coronary artery
bypass graft (CABG) surgery versus conser-vative care in patents with SIHD performed several
decades ago suggested a survival beneﬁt for CABG in
patients with extensive anatomic disease, in whom a
large amount of myocardium was at risk (left main
disease, 3-vessel disease, and possibly 2-vessel dis-
ease involving the proximal left anterior descending
coronary artery) (7). Ischemia on an exercise stress
test also identiﬁed patients in whom mortality was
reduced with CABG compared with medical therapy
(MT) (7). These earlier randomized trials of CABG
versus MT, however, antedated the more contem-
porary use of “disease-modifying” pharmacological
interventions, including statins, inhibitors of the
renin-angiotensin-aldosterone axis, and antiplatelet
agents that individually have been shown to reduce
death and MI in placebo-controlled trials. The aggre-
gate use of such secondary prevention therapies,
along with lifestyle interventions, such as cigarettesmoking cessation, diet, and regular exercise, has
been referred to as optimal medical therapy (OMT),
or GDMT (1,2).
More recently, the beneﬁts of routine revasculari-
zation in SIHD have been questioned by the similar
rates of death and MI observed in OMT-treated
patients with and without percutaneous coronary
intervention (PCI) in the COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive
Drug Evaluation) trial, and with and without PCI or
CABG in the BARI 2D (Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes) trial (8,9).
It may be argued that revascularization in SIHD
may not be beneﬁcial because not all anatomically
obstructive coronary stenoses produce ischemia,
or because not all high-grade coronary stenoses
result in cardiac death and/or MI, or conversely,
because most cases of cardiac death and/or MI arise
from angiographically mild coronary lesions, which
are not revascularized. However, some observa-
tional studies and hypothesis-generating substudy
data from randomized trials suggest that the
magnitude of ischemia is associated with adverse
outcomes and that alleviation of ischemia may
improve prognosis. Conversely, credible studies
drawn from different (or even the same!) data-
sets have cast doubt on this premise. And im-
portantly, often lost in this discussion is the
extent to which revascularization improves QoL, a
worthwhile goal, assuming noninferior rates of
“hard” adverse event endpoints and reasonable
cost-effectiveness.
Recent clinical practice guidelines from the
United States and Europe, as well as U.S. appro-
priate use criteria, endorse GDMT for all patients
with SIHD, but recommend (with variable levels of
certainty) consideration of revascularization in pa-
tients with signiﬁcant ischemia or symptoms that
persist despite MT (10–14). Despite this uncertainty,
highly enthusiastic proponents of both routine and
selective revascularization for SIHD patients with
ischemia may be found, and nearly everyone has an
opinion. Indeed, attitudes run so strongly on this
topic that it may be questioned whether clinical
equipoise exists, although, when pushed, nearly
all agree that deﬁnitive trials addressing the role
of revascularization in optimally treated SIHD
patients with substantial ischemia have not yet
been performed.
The purpose of this review is to describe the
evidence supporting the initial strategies of rou-
tine revascularization plus GDMT versus GDMT
alone, with revascularization reserved for MT failure
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83(e.g., progressive or refractory symptoms or the
development of ACS), in patients with SIHD and
moderate or severe ischemia. Each perspective is
summarized in Table 1. The evidence is presented as
an internal debate, and the reader may naturally
gravitate to one position or the other. We recommend
that those with a strong preconceived preference pay
particular attention to the data supporting the oppo-
site view. The authors believe that on the basis of the
present level of evidence, a justiﬁable case can be
made for either an initial strategy of upfront revas-
cularization (with PCI or CABG, as determined by the
local heart team) plus GDMT, or an initial strategy of
GDMT alone. The equipoise expressed in this docu-
ment served as the impetus for the collaborative
ISCHEMIA trial (International Study of Comparative
Health Effectiveness with Medical and Invasive Ap-
proaches), as described later.
THE CASE FOR ROUTINE REVASCULARIZATION
IN PATIENTS WITH SIHD AND ISCHEMIA
OVERVIEW. Revascularization may beneﬁt SIHD pa-
tients by preventing death, MI, and unstable anginaTABLE 1 Supportive Evidence for an Initial Routine Revascularization
Favors an Initial Strategy of
1. Most data from large observational studies and from within randomized
death and MI.
2. Revascularization relieves ischemia to a greater extent than the best me
3. Several large-scale observational studies and some randomized data hav
revascularization compared with medical therapy in SIHD.
4. Both PCI and CABG revascularization strategies are continually being im
documented to be more effective in relieving ischemia and reducing dea
5. Nearly all studies suggest that routine revascularization more effectively
QoL more than GDMT for at least several years. The rates converge over
required revascularization for progressive symptoms.
6. Adherence to GDMT (especially multiple daily medications) is difﬁcult an
reduction in symptoms and avoidance of antianginal medications achieva
7. An initial strategy of routine revascularization does not preclude patient
thrombosis. However, by reducing the requirement for antianginal medic
to reduce MI and death.
Favors an Initial Con
1. GDMT is necessary in all SIHD patients, whether or not revascularization
an alternative to antianginal medication, not an alternative to GDMT. Pa
outcomes.
2. Recent studies in the current GDMT era have not demonstrated a link be
3. PCI, the most common form of revascularization, has never been shown
4. Medical therapy is continually being improved. Prolonged dual antiplate
death, MI, and stroke following remote MI, and stent thrombosis and M
or without concomitant statin treatment, and may reduce death and MI.
5. The QoL beneﬁt from revascularization appears to be time limited, more
absence of sham procedure control groups.
6. Because revascularization has not been proven to reduce death or MI in
to see if symptom relief is adequate. An initial trial of GDMT without rev
7. Routine revascularization in SIHD is more costly to the patient and socie
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; GDMT ¼ guideline-
PCI ¼ percutaneous coronary intervention; PCSK9 ¼ proprotein convertase subtilisin/ke(which, even if successfully managed with urgent
hospitalization and treatment, may be more dis-
tressing for patients than a controlled elective pro-
cedure), and by improving QoL. More than 25 years
ago, Ellis et al. (15) reported that the incidence of
anterior MI increases with the severity of untreated
left anterior descending coronary artery lesions.
The extent of incomplete anatomic revasculariza-
tion after PCI and CABG is strongly associated
with subsequent death, MI, and recurrent angina
requiring rehospitalization (16,17). Furthermore,
large-scale, nonrandomized studies have reported
improved prognosis with revascularization in SIHD.
In a propensity-matched observational analysis in
39,131 patients with SIHD, early revascularization
was associated with fewer deaths and MI during
4-year follow-up, compared with initial MT alone
(Figure 1) (18). Similarly, in a study of 15,223 patients
with newly diagnosed SIHD by coronary computed
tomographic angiography (CCTA), patients with
high-risk CAD in whom revascularization was per-
formed within 90 days had signiﬁcantly reduced
mortality at a median 2.1-year follow-up com-
pared with those treated medically (2.3% vs. 5.3%,Strategy Plus GDMT Versus GDMT Alone in Patients With SIHD
Routine Revascularization
trials suggest a relationship between ischemia and subsequent
dical therapy.
e demonstrated a reduction in spontaneous MI and death with
proved, with contemporary stent technologies and surgical techniques
th and MI than prior approaches.
reduces angina and the need for antianginal medications, and improves
time only in part because many GDMT patients have “crossed over” and
d not routinely achieved. Many patients prefer the more immediate
ble with revascularization compared with GDMT.
s beneﬁtting from GDMT that inhibit coronary atherosclerosis and
ations, revascularization may facilitate compliance with GDMT proven
servative Strategy
is performed, because it prevents MI and death. Revascularization is
tients who undergo PCI and CABG must still take GDMT to optimize
tween ischemia and death or MI.
in randomized trials to improve survival in SIHD.
let therapy results in reductions in the composite rate of cardiovascular
I after stents. PCSK9 inhibitors reduce LDL by $50% in patients with
so for PCI than for CABG. There are challenges to assessing QoL in the
SIHD, a trial of GDMT should be tried before elective revascularization
ascularization does not increase the risk of death or MI.
ty.
directed medical therapy; LDL ¼ low-density lipoprotein; MI ¼ myocardial infarction;
xin type 9; QoL ¼ quality of life; SIHD ¼ stable ischemic heart disease.
FIGURE 1 Propensity-Matched Analysis in 39,131 Canadian Patients With SIHD
Undergoing Early Revascularization (n ¼ 23,992) or Treated Conservatively (n ¼ 15,139)
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Over 4 years of follow-up, signiﬁcant reductions in death (A) and myocardial infarction
(B)wereobservedwith revascularization.Adaptedwithpermission fromWijeysunderaet al. (18).
CI¼ conﬁdence interval; HR¼ hazard ratio; SIHD¼ stable ischemic heart disease.
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84p ¼ 0.008; adjusted hazard ratio [HR]: 0.38; 95%
conﬁdence interval [CI]: 0.18 to 0.83) (19). No sig-
niﬁcant difference in mortality with revasculari-
zation was observed in lower-risk patients without
high-risk CAD. Finally, in a propensity-matched
study of 1,866 patients in New York State with
SIHD undergoing cardiac catheterization, PCI com-
pared with MT was associated with reduced 4-year
rates of death or MI (16.5% vs. 21.2%; adjusted HR:
1.49; 95% CI: 1.16 to 1.93) (20). Although not ran-
domized, these real-world studies included higher-
risk patients than the COURAGE and BARI 2D trials(8,9), and with many more events had substantially
greater power to detect reductions in death and MI
between treatments.
These studies reported outcomes with anatomi-
cally driven revascularization. Targeting revasculari-
zation to lesions causing substantial ischemia may
further improve results. The angiogram is a poor
discriminator of physiological lesion signiﬁcance.
Many lesions that appear angiographically severe
may not produce ischemia, and conversely, ischemia
may be present despite a benign angiographic
footprint (21,22).
OBSERVATIONAL DATA DEMONSTRATE A STRONG
RELATIONSHIP BETWEEN THE EXTENT OF ISCHEMIA
AND SUBSEQUENT DEATH AND/OR MI, AND A POSSIBLE
BENEFIT FROM REVASCULARIZATION. Most single-
photon emission computed tomography (SPECT)
myocardial perfusion imaging studies have demon-
strated a strong relationship between the extent of
ischemia and prognosis. In 1,137 patients with chest
pain or suspected CAD in whom thallium-201 SPECT
was performed, a strong graded association was pre-
sent between the number of abnormal segments
and the 6-year rate of cardiac death and MI (23). In a
study of 205 patients with angiographically proven
CAD, freedom from cardiac death or MI at 10 years
was greater in patients with a normal compared
with an abnormal thallium-201 SPECT (83% vs. 58%;
p ¼ 0.005) (24). In a study of 1,126 asymptomatic
patients, the presence of $10% ischemia by SPECT
was independently associated with death or MI at
median follow-up of 6.9 years (HR: 2.67; 95% CI:
1.31 to 5.44; p ¼ 0.007) (25). Among 10,627 patients
in whom a quantitative stress SPECT study was
performed (671 of whom were treated with early
revascularization), the mean 1.9-year rate of cardiac
mortality in nonrevascularized patients increased
monotonically, from 0.7% in those with no ischemia
to 6.7% in those with >20% ischemia (Figure 2) (26).
After accounting for baseline variables and the pro-
pensity for revascularization, a strong relationship
was present between the percentage of myocardial
ischemia and cardiac mortality.
In the COURAGE serial nuclear substudy, 314
patients underwent rest/stress SPECT before treat-
ment and at 6 to 18 months (mean 374  50 days),
with the amount of ischemia assessed at a blinded
core laboratory (27). A strong graded relationship was
present between the amount of residual ischemia
on the 6- to 18-month test and subsequent death or
MI (p ¼ 0.001), which was attenuated after adjust-
ment for baseline variables and treatment (p ¼ 0.09).
Similarly, long-term freedom from death or MI was
FIGURE 2 Cardiac Mortality as a Function of Total Ischemic Myocardium at a Mean Follow-Up Time of 1.9  0.6 Years
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Cardiac mortality as a function of total ischemic myocardium is shown at a mean follow-up time of 1.9  0.6 years in 10,627 patients at
Cedars-Sinai Medical Center without previous myocardial infarction or revascularization who underwent exercise or adenosine thallium 201
single-photon emission computed tomography myocardial perfusion scintigraphy. Outcomes are shown according to whether elective
revascularization was versus was not performed within 60 days. Patients with a greater percentage of ischemic myocardium had a greater
survival beneﬁt with revascularization. (A) Unadjusted analysis. (B) Log hazard ratio of cardiac mortality for revascularization versus medical
therapy as a function of % ischemic myocardium from a Cox proportional hazards regression model. *p < 0.001. Adapted with permission from
Hachamovitch et al. (26).
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85greater in patients achieving versus not achieving
$5% reduction in ischemia (whether attained by
PCI or OMT alone), especially in those with at least
moderate ($10%) ischemia at baseline. Of note, PCI
resulted in a substantial reduction in quantitative
ischemia from the baseline to the follow-up SPECT
study (8.2% vs. 5.5%; p < 0.0001). By contrast,
despite excellent compliance with GDMT in the
COURAGE trial, no reduction in ischemia from base-
line to follow-up occurred with MT (8.6% vs. 8.1%;
p ¼ 0.93) (Figure 3).The adverse prognostic implications of ischemia
have been observed with other noninvasive imaging
techniques and with invasive physiological lesion
assessment. Among 7,061 patients at 4 centers in
whom a clinically indicated rest/stress rubidium-82
positron emission computed tomography was per-
formed, the adjusted risk of cardiac death at a median
follow-up of 2.2 years increased 84% for each
10% of ischemic myocardium (p < 0.0001) (28). In
another study, stress echocardiography was perfor-
med in 14,140 patients at 2 Italian institutions (29).
FIGURE 3 Reduction in Inducible Ischemia From Baseline to 6 to 18 Months
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Reduction in inducible ischemia from baseline to 6 to 18 months is shown in patients treated with OMT with versus without a strategy of routine
upfront PCI, as assessed by myocardial perfusion scintigraphy. Left graph: with routine upfront PCI; right graph: without. The reduction
in ischemia in the PCI arm was signiﬁcant, whereas there was no signiﬁcant reduction in ischemia with OMT. Adapted with permission from Shaw
et al. (27). CI ¼ conﬁdence interval; OMT ¼ optimal medical therapy; PCI ¼ percutaneous coronary intervention.
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86At median 2.5-year follow-up, the presence of
ischemia was a strong independent predictor of
mortality in both diabetic patients (HR: 1.71; 95% CI:
1.34 to 2.18; p < 0.0001) and nondiabetic patients
(HR: 1.54; 95% CI: 1.32 to 1.80; p < 0.0001).
Finally, identiﬁcation of hemodynamically signiﬁcant
ﬂow-limiting lesions during hyperemia with adeno-
sine in the cardiac catheterization laboratory (frac-
tional ﬂow reserve [FFR]) has been correlated with
death and MI in medically treated patients. In a
collaborative meta-analysis, the rates of death or MI
and major adverse cardiac events (MACE) were
inversely related to FFR at a median 16-month follow-
up (Figure 4) (30).
Observational studies further support the potential
role of routine revascularization to improve prog-
nosis in patients with moderate or severe ischemia.
In a propensity-controlled multivariable analysis
from Cedars-Sinai Medical Center, 2-year rates of
cardiac death were lower with revascularization
within 60 days in patients with moderate or severe
ischemia (cutoff w12.5% of the left ventricle) by
SPECT (Figure 2) (26). In a subsequent investigation
from the same center in 13,969 patients with a mean
8.7-year follow-up, early revascularization in patientswith $10% inducible ischemia by SPECT was associ-
ated with improved late survival, unless a large ﬁxed
defect was present (31). Early revascularization in
patients with $10% myocardial ischemia was associ-
ated with improved survival, even in those $75 years
of age (32). In a Mayo Clinic study, a survival beneﬁt
among diabetic patients with CABG compared with
MT or PCI was noted only in those with a high-risk
SPECT scan (33). Finally, in an adjusted study-level
meta-regression of 90 cohorts in which FFR was
assessed, revascularization was associated with a
lower 1-year rate of death or MI when FFR was <0.90
(30).
RANDOMIZEDTRIAL DATA SUGGEST REVASCULARIZATION
IS SAFE AND REDUCES DEATH AND/OR MI AND/OR
IMPROVES QoL, ESPECIALLY WHEN SUBSTANTIAL
ISCHEMIA IS PRESENT. In the MASS II trial (Medicine,
Angioplasty or Surgery Study), 611 patients with
proximal multivessel disease and documented
ischemia were randomly assigned to CABG, PCI,
or OMT (34). The 10-year mortality rates in the 3
groups were 25.1%, 24.9%, and 31.0%, respectively
(p ¼ 0.09). The 10-year MI rates were 10.3%, 13.3%,
and 20.7%, respectively (p < 0.01). Freedom from
FIGURE 4 Relationship Between FFR and 1-Year MACE According to Whether or Not Revascularization Was Performed
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87angina at 10 years was 64% with CABG, 59% with PCI,
and 43% with OMT (p < 0.001).
In the COURAGE trial, randomization of 2,287
patients to PCI plus OMT versus OMT alone did not
reduce the long-term rate of death or MI (8). Nor,
however, did PCI worsen prognosis, and crossover to
PCI for progressive symptoms or ACS was required in
32% of OMT patients during a median 4.6-year follow-
up. Moreover, patients randomized to PCI had less
documented angina, were more likely to be angina-
free (despite requiring fewer nitrates and calcium-
channel blockers), and had improved QoL for up to
3 years (8,35). The reduction in angina (assessed by
the Seattle Angina Questionnaire) with PCI versus
OMT was most evident in those with the greatest
level of baseline angina (35).
In the BARI 2D trial, 2,368 patients with type 2
diabetes (90% with SIHD) were randomized to prompt
revascularization with intensive MT or to intensive
MT alone, with randomization stratiﬁed by intended
PCI versus CABG (9). The 5-year rates of death
(the primary endpoint) and MACE (death, MI, or
stroke) were not signiﬁcantly different with either
strategy. However, patients in the CABG stratum had
more advanced CAD (including more triple-vessel and
proximal left anterior descending coronary artery
disease) than those in the PCI stratum, and patients
randomized to CABG versus intensive MT had lower5-year rates of MACE (22.4% vs. 30.5%; p ¼ 0.01),
driven by less MI (7.4% vs. 14.6%). In patients with
less extensive CAD, there was no difference in MACE
with PCI versus intensive MT. Compared with inten-
sive MT, prompt revascularization resulted in signif-
icantly greater freedom from angina for up to 4 years
(36). Most measures of QoL through the 4-year follow-
up were also improved with routine revascularization
compared with intensive MT only (37), and revascu-
larization was ultimately required in 42% of MT
patients during follow-up (9).
Meta-analyses have also shown reduced mortality
and greater angina relief with early routine revascu-
larization versus MT. In a systematic review and
meta-analysis of 12 randomized trials comparing PCI
versus MT in 7,182 SIHD patients, Pursnani et al. (38)
found a strong trend for lower mortality with PCI
(risk ratio [RR]: 0.85; 95% CI: 0.71 to 1.01; p ¼ 0.07).
Others have reported similar trends (39,40). From 17
trials of PCI versus OMT in 7,513 stable patients with
ischemia (some with recent MI), Schömig et al. (41)
reported that PCI was associated with a signiﬁcant
reduction in all-cause mortality (odds ratio [OR]:
0.80; 95% CI: 0.64 to 0.99). Jeremias et al. (42) per-
formed the largest meta-analysis to date from 28
trials of revascularization versus MT in 13,121 patients
with nonacute CAD. Revascularization was associated
with a reduction in mortality (OR: 0.74; 95% CI: 0.63
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88to 0.88), a difference that was signiﬁcant for both
CABG (OR: 0.62; 95% CI: 0.50 to 0.77) and PCI
(OR: 0.82; 95% CI: 0.68 to 0.99). PCI was also asso-
ciated with greater freedom from angina compared
with MT in a meta-analysis of 12 randomized trials
in SIHD (RR: 1.20; 95% CI: 1.06 to 1.37), a beneﬁt
that was present at follow-up durations #1 year, 1 to
5 years, and $5 years (38).
Of note, bare-metal stents (BMS) were used in most
PCI versus MT trials to date (including the MASS II,
COURAGE, and BARI 2D studies). First-generation
drug-eluting stents (DES) markedly reduce recur-
rent ischemia compared with BMS (43), resulting in
fewer hospitalizations for repeat revascularization
(44). Compared with BMS and ﬁrst-generation DES,
second-generation DES may further reduce death
and MI, and enhance event-free survival (39,45,46).
In a comprehensive network meta-analysis of revas-
cularization versus MT in SIHD in which stent type
was considered (100 trials, 93,553 patients, 262,090
patient-years of follow-up), PCI with everolimus-
eluting stents compared with MT was associated
with signiﬁcant 25%, 22%, and 73% reductions in
death, death or MI, and repeat revascularization,
respectively (Figure 5) (47). Similar beneﬁts were
noted with CABG compared with MT, and in analyses
that excluded trials of patients with recent MI or
stabilized ACS.
Outcomes may be further improved by a routine
revascularization strategy in patients with more
extensive ischemia. Only w33% of patients in
COURAGE had at least moderate ($10%) ischemia at
baseline, either measured quantitatively (27) or site
assessed (48); w40% of patients had <5% ischemia
(27). Ischemia, as evidenced by FFR, may predict
which patients and lesions are likely to beneﬁt from
routine revascularization versus GDMT alone. In the
DEFER trial, 91 patients with FFR >0.75 were ran-
domized to balloon angioplasty versus MT (49). The
2-year rates of death, MI, or repeat revascularization
were similar in the deferral and PCI groups (89% vs.
83%, respectively). In the FAME (Fractional Flow
Reserve versus Angiography for Multivessel Evalua-
tion) trial, FFR was performed in 1,005 patients with
multivessel disease undergoing PCI with ﬁrst-
generation DES. Patients were randomized to treat-
ment of all angiographically signiﬁcant lesions,
versus only lesions with FFR #0.80. Compared with
anatomically based revascularization, FFR-guided PCI
resulted in lower rates of the primary endpoint of
death, MI, or repeat revascularization at 1 year (13.2%
vs. 18.3%; p¼ 0.02), and of death or MI at 2 years (8.4%
vs. 12.9%; p ¼ 0.02) (50,51). These data, consistent
with earlier observational studies, suggest that theprognosis of non–ischemia-producing lesions without
revascularization is favorable.
By contrast, the FAME-2 trial demonstrated worse
outcomes with an initial MT approach in ﬂow-limiting
lesions. In the FAME-2 trial, 888 of a planned 1,632
patients with SIHD and 1 or more lesions with an
FFR #0.80 (i.e., ischemia) were randomized to PCI
with second-generation DES plus GDMT versus GDMT
alone (52). The trial was stopped early because of
excess events in the GDMT arm. The 2-year primary
endpoint of death, MI, or urgent revascularization
occurred in 8.1% of PCI patients versus 19.5% of
GDMT patients (HR: 0.39; 95% CI: 0.26 to 0.57;
p < 0.001), driven by fewer urgent revascularizations
(4.0% vs. 16.3%; p < 0.001), including those triggered
by MI or severe unstable angina (3.4% vs. 7.0%;
p ¼ 0.01). Class II to IV angina was also signiﬁcantly
more frequent in the GDMT arm during follow-up,
and PCI was required in 40.6% of GDMT-assigned
patients within 2 years for refractory symptoms or
ACS. Although there was no signiﬁcant difference in
the composite rate of death or MI, landmark analysis
showed that periprocedural MI rates were increased
with PCI, whereas MI occurred less frequently in the
PCI group compared with the GDMT group between
8 days and 2 years. Similarly, in a meta-analysis
of 12 randomized trials of PCI versus OMT with
37,548 patient-years of follow-up, PCI compared
with MT was associated with a signiﬁcant 23%
reduction in spontaneous MI, which paralleled a
trend toward reduced mortality (53). Spontaneous
MI has been strongly associated with subsequent
mortality, whereas most periprocedural MIs are not
clinically relevant (54).
Finally, because most periprocedural MIs do not
have major clinical consequence (54), their inclusion
in a primary composite death or MI endpoint of prior
trials may have statistically masked an isolated mor-
tality beneﬁt of revascularization in SIHD patients
with documented ischemia. Three randomized trials
of PCI versus MT in SIHD have been performed in
which 1,557 patients had evidence of ischemia on
noninvasive stress imaging or FFR before randomi-
zation (the COURAGE baseline nuclear substudy, the
FAME-2 study, and the SWISSI [Silent Ischemia After
Myocardial Infarction] II trial [which enrolled stabi-
lized patients after acute MI]) (48,52,55). In a meta-
analysis of these 3 trials, routine PCI compared with
MT was associated with lower 3-year mortality
(HR: 0.52; 95% CI: 0.30 to 0.92; p ¼ 0.02), with no
heterogeneity between studies (56).
MEDICATION DISUTILITY AND PATIENT PREFERENCE.
Adherence to biology-altering medications, such
FIGURE 5 Network Meta-Analysis Comparing Different Revascularization Modalities With MT
Rate ratio (95% CrI)
All cause mortality
Rate ratio (95% CrI)
(95 trials; 93,553 patients)
CABG v medical treatment
PTCA v medical treatment
BMS v medical treatment
PES v medical treatment
SES v medical treatment
E–ZES v medical treatment
R-ZES v medical treatment
EES v medical treatment
CABG v medical treatment
PTCA v medical treatment
BMS v medical treatment
PES v medical treatment
SES v medical treatment
E–ZES v medical treatment
R-ZES v medical treatment
EES v medical treatment
CABG v medical treatment
PTCA v medical treatment
BMS v medical treatment
PES v medical treatment
SES v medical treatment
E–ZES v medical treatment
R-ZES v medical treatment
EES v medical treatment
0.80 (0.70 to 0.91)
0.85 (0.68 to 1.04)
0.92 (0.79 to 1.05)
0.92 (0.75 to 1.12)
0.91 (0.75 to 1.10)
0.88 (0.69 to 1.10)
0.65 (0.42 to 1.00)
0.75 (0.59 to 0.96)
0.79 (0.63 to 0.99)
0.88 (0.70 to 1.11)
1.04 (0.84 to 1.27)
1.18 (0.88 to 1.54)
0.94 (0.71 to 1.22)
0.80 (0.56 to 1.10)
0.82 (0.52 to 1.26)
0.75 (0.55 to 1.01)
0.81 (0.70 to 0.94)
0.83 (0.70 to 0.97)
0.99 (0.85 to 1.12)
1.06 (0.87 to 1.27)
0.96 (0.79 to 1.13)
0.85 (0.67 to 1.05)
0.81 (0.59 to 1.10)
0.78 (0.63 to 0.96)
Myocardial infarction
(92 trials; 90,472 patients)
Death or myocardial infarction
(88 trials; 89,373 patients)
0.1 0.3 1 3
Favors
Revascularization
Favors
Medical Treatment
Estimated risk rate ratios (95% credible intervals) are shown for death, MI, and the composite of death or MI. Compared with MT, a reduction in
death was observed with EES, R-ZES, and CABG; a reduction in MI was observed with CABG; and a reduction in the composite of death or MI was
observed with EES and CABG. Adapted with permission from Windecker et al. (47). BMS ¼ bare-metal stent(s); CrI ¼ credible interval;
EES ¼ everolimus-eluting stent(s); E-ZES ¼ fast-release zotarolimus-eluting stent(s); MT ¼ medical therapy; PES ¼ paclitaxel-eluting stent(s);
PTCA ¼ percutaneous transluminal coronary angioplasty; R-ZES ¼ slow-release zotarolimus eluting stent(s); SES ¼ sirolimus-eluting stent(s);
other abbreviations as in Figure 4.
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89as aspirin and statins, reduces death and MI in
SIHD patients treated with or without revas-
cularization (1,2,57). In addition to potentially im-
proving prognosis, routine revascularization reduces
the requirement for antianginal medications, asobserved in the COURAGE trial (8). Recent studies
have emphasized the cost and inconvenience
(disutility) to the patient of taking medications.
Participants of 2 large surveys were willing to sacri-
ﬁce 4 and 6 months of life, respectively, to avoid
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90taking a daily pill (58,59). A meta-analysis from 20
studies and 376,162 patients examining usage of 7
drug classes that prevent cardiovascular disease re-
ported average 2-year adherence rates of 50% for
primary prevention and 66% for secondary preven-
tion, with few differences between drug classes (60).
Recent reports have emphasized the importance of
patient-centered care and shared decision making,
taking into account patient goals and preferences
when choosing between therapies, especially when
the prognosis of alternative approaches are roughly
similar (61). Beyond considerations of whether
revascularization reduces death and MI in SIHD,
many patients favor the more immediate reduction
in symptoms achievable with PCI and CABG, and
avoidance of antianginal medications.
Finally, as the disutility of taking medications in-
creases with the number of daily pills, reducing the
requirement for antianginal medications may facili-
tate compliance with GDMT that reduces MI and
death, such as statins. Revascularization may serve as
a “wake-up call” to patients, and stimulate compli-
ance with secondary prevention. In fact, GDMT
adherence may be increased after PCI, compared with
more conservative care (62).
THE CASE FOR INITIAL GDMT IN
PATIENTS WITH SIHD AND ISCHEMIA
OVERVIEW. GDMT should be initiated in all
SIHD patients, whether or not revascularization isFIGURE 6 Effect of OMT on Clinical Outcomes in Patients Undergoin
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OMT signiﬁcantly lowered the risk of death throughout the 5-year follow
was independently associated with improved survival throughout follow-
patients (HR: 0.65; 95% CI: 0.49 to 0.86; pinteraction ¼ 0.44). Adapted
Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery; operformed. GDMT consists of lifestyle and pharma-
cological interventions that lower the risk of death
and MI; revascularization is not a substitute for this.
Although revascularization might be considered a
reasonable alternative to antianginal medications
to treat angina, disease-modifying medications are
still necessary to improve survival (Figure 6) (57,63).
Comprehensive risk factor control, although not
commonly achieved, is associated with a 50% reduc-
tion in mortality over 5 years in SIHD patients
with diabetes, with or without revascularization
(64). Adherence to GDMT following revascularization
in the SYNTAX (Synergy Between Percutaneous Cor-
onary Intervention With TAXUS and Cardiac Surgery)
trial was suboptimal in the PCI group, and even worse
in the CABG group (57). Clearly, strategies are
required to improve GDMT adherence, whether or
not early revascularization is performed.
Recent studies suggest that, in the contemporary
GDMT era, the extent of ischemia is not related to
the risk of death or MI in patients with SIHD, and
that revascularization does not improve prognosis,
regardless of the extent of ischemia. If true, then the
only reason to routinely revascularize SIHD patients
would be to improve QoL. If an initial trial of GDMT
does not increase the risk of death or MI, it is
difﬁcult to justify revascularization in patients with
absent or mild symptoms not treated with anti-
anginal therapy, because all procedures have
inherent risks. Furthermore, as MT improves and
event rates decrease, possible early harm fromg PES Implantation and CABG in the SYNTAX Trial
1–year 3–year 5–year
-up. In a Cox regression model, OMT as a time-dependent covariate
up both in PCI patients (HR: 0.70; 95% CI: 0.48 to 0.998) and CABG
with permission from Iqbal et al. (57). SYNTAX ¼ Synergy Between
ther abbreviations as in Figures 1, 3, 4, and 5.
FIGURE 7 Baseline Severity of Ischemia and Outcomes by Treatment Group
in the COURAGE Trial
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Cumulative rates of all-cause death or MI are shown according to randomized treatment
assignment in patients with no-to-mild ischemia and moderate-to-severe ischemia on
myocardial perfusion imaging at baseline in the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) trial. (A) No-to-mild ischemia.
(B) Moderate-to-severe ischemia. Ischemia severity was determined by the participating
sites, and was not associated with risk of death or MI. PCI did not reduce death or MI in
patients with moderate or severe ischemia. Adapted with permission from Shaw et al. (48).
Abbreviations as in Figures 3 and 4.
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91routine revascularization—death, MI, and stroke—
become relatively more important in weighing the
potential beneﬁts and risks of performing PCI or
CABG.
OBSERVATIONAL DATA SUGGEST THE EXTENT OF
ISCHEMIA IS NOT RELATED TO DEATH AND MI IN
THE CONTEMPORARY GDMT ERA. In the COURAGE
serial nuclear substudy, a strong relationship was
found between the extent of core laboratory–assessed
residual ischemia at 6 to 18 months and subsequent
death or MI in 314 patients, but this was not signiﬁ-
cant after multivariable adjustment (27). This sub-
study included w14% of enrolled patients and may
not be representative of the entire COURAGE popu-
lation. Although there was a signal that ischemia
reduction was associated with better outcomes, and
that PCI was associated with a greater degree of
ischemia reduction than OMT, the critical link of
whether PCI was causally associated with fewer car-
diac events was not analyzed. Thus, this substudy
was underpowered and hypothesis-generating. In a
separate, larger COURAGE report, in which site in-
vestigators evaluated the extent of ischemia in 1,381
patients with baseline SPECT imaging, no signiﬁcant
relationship was present between the rates of death
and MI in those with $3 versus <3 ischemic segments
(Figure 7) (48). In a follow-up COURAGE core labora-
tory study in 621 patients, the extent of baseline
ischemia did not correlate with the rate of death, MI,
or ACS after a mean follow-up of 4.7 years, whereas
the angiographic extent of atherosclerosis correlated
with events (Figure 8) (65). These COURAGE trial an-
alyses assessed death and MI rates differently. In the
serial nuclear substudy, outcomes after repeat SPECT
did not include events between randomization and
6 to 18 months, or events in patients who did not
return for the follow-up stress test, and events were
not reported according to treatment group. By
contrast, in the substudies that evaluated prognosis
using baseline ischemia, all events during follow-up
were ascertained, and event rates were reported ac-
cording to treatment group.
Other recent studies have also failed to demon-
strate a link between ischemia and prognosis. In a
post-hoc analysis from the BARI 2D trial, the prog-
nostic impact of SPECT performed 1 year after
randomization was examined in 1,505 patients, as
assessed by a core laboratory (66). Increasing severity
of ischemia did not predict greater risk of death or
cardiovascular events. In an observational study,
Cleveland Clinic investigators compared survival of
asymptomatic patients with previous revasculariza-
tion and documented ischemia on SPECT 5 years afterthe initial revascularization with a mean 5.7-year
follow-up. The severity of ischemia was not associ-
ated with all-cause death, regardless of whether
early repeat revascularization was performed or MT
continued (67). In the STICH (Surgical Treatment for
FIGURE 8 Ischemia Severity, Anatomic Burden, and Outcomes in COURAGE
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Freedom fromdeath,MI, or NSTE-ACS is shown by percent ischemicmyocardium and burden
of angiographic atherosclerosis. (A) Percent ischemic myocardium. (B) Burden of angio-
graphic atherosclerosis. Thenumber of patients pertaining to each colored curve is shownper
year of follow-up. The Cedars-Sinai Nuclear Core Laboratory determined the percent
ischemicmyocardium at baseline. Atherosclerotic burdenwas determined by a custom score,
accounting for the number and speciﬁc diseased coronary arteries, and proximal versus
nonproximal location. Ischemic burden was not associated with events, in contrast to
anatomic burden, which was. PCI did not reduce the event rate in patients with high ischemic
or anatomic burden. Adapted with permission from Mancini et al. (65). NSTE-ACS ¼ non–
ST-segment elevation acute coronary syndrome; other abbreviations as inFigures 3,4, and 7.
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92IsChemic Heart Failure) trial of CABG versus MT in
SIHD patients with left ventricular ejection fraction
(LVEF) #35%, at a median follow-up of 4.7 years,
the presence of inducible ischemia at baseline
did not identify patients with a worse prognosis
(68). The CLARIFY (Prospective ObservationalLongitudinal Registry of PatientsWith Stable Coronary
Artery Disease) registry enrolled 32,105 outpatients
with prior MI, of whom 20,291 had undergone a
noninvasive test for ischemia within 12 months of
enrollment (69). Anginal symptoms (with or without
ischemia), but not silent ischemia, were associated
with an increased 2-year rate of cardiovascular death
or MI. These studies, performed in an era of more
intensive MT, are distinct from earlier reports in which
strong associations between ischemia and outcomes
were observed.
RANDOMIZED TRIALS SUGGEST REVASCULARIZATION
DOES NOT REDUCE DEATH OR MI, EVEN IF ISCHEMIA
IS PRESENT, AND DOES NOT PRODUCE A DURABLE
IMPROVEMENT IN QoL. In the COURAGE trial, after a
median 4.6-year follow-up, there was no signiﬁcant
difference between PCI plus OMT versus OMT alone
in the primary endpoint of death or MI (19.0% vs.
18.5%, respectively; HR: 1.05; 95% CI: 0.87 to 1.27;
p ¼ 0.62) (8). Although high-risk subgroups were
identiﬁed, none had an improved prognosis with PCI.
Similarly, in the BARI 2D study, 5-year survival rates
in type 2 diabetic patients did not differ signiﬁcantly
between the revascularization and MT groups (88.3%
vs. 87.8% respectively; p ¼ 0.97); MACE rates were
also similar (77.2% vs. 75.9% respectively; p ¼ 0.70)
(9). A lower rate of MI was reported in the BARI 2D
CABG stratum with revascularization compared with
MT, although CABG-related MI was not ascertained,
and this subgroup ﬁnding should be considered
hypothesis-generating. BARI 2D patients who ach-
ieved excellent risk factor control had one-half the
death rate of those with poor risk factor control (64).
Meta-analyses of SIHD strategy trials that exclude
patients with recent ACS do not support a difference
in prognosis between routine revascularization and
MT only. Before the COURAGE trial, Katritsis
and Ioannidis (70) performed a meta-analysis of
11 randomized trials with 2,950 patients comparing
PCI (with balloon angioplasty or BMS) to conservative
treatment. PCI did not reduce the rates of death or
MI. Addition of the results from the COURAGE trial to
this meta-analysis did not alter the estimate of PCI
on mortality (71). Schömig et al. (41) reported, in a
meta-analysis of 17 trials, that PCI was associated
with a signiﬁcant reduction in all-cause mortality.
However, in 4 trials, patients were treated with CABG
as well as PCI, 1 trial included patients with MI within
3 months, and 4 trials included MI patients within
4 weeks. If the studies that included CABG and
recent MI patients are excluded from the analysis, a
signiﬁcant mortality difference between PCI and
medical therapy is no longer present (OR: 0.91;
FIGURE 9 Meta-Analysis of PCI and MT Versus MT Alone in Patients With Documented Myocardial Ischemia
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(A) Death. (B) Nonfatal MI. This meta-analysis required 50% statin use and only included studies of SIHD that directly compared the 2 randomized groups.
The addition of PCI to MT did not reduce the incidence of death or MI as compared with MT alone. Adapted with permission from Stergiopoulos et al. (73).
OR ¼ odds ratio; other abbreviations as in Figures 3, 4, and 5.
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9395% CI: 0.74 to 1.12). Trikalinos et al. (72) performed
a network meta-analysis of 61 randomized trials
(n ¼ 25,388) comparing balloon angioplasty, BMS, and
DES with each other and with MT in SIHD. None of the
PCI modalities was associated with reduced death or
MI. The RR for comparisons between DES and MT was
0.96, (95% CI: 0.60 to 1.52) for death, and 1.15
(95% CI: 0.73 to 1.82) for MI. Stergiopoulos et al. (73)
performed a meta-analysis of the subset of patients
from 5 SIHD strategy trials (5,286 patients) in which
stents and statins were used in more than 50% of
patients, with ischemia diagnosed by stress testing or
FFR. There were no signiﬁcant differences in event
rates for PCI plus GDMT versus GDMT alone for death
or nonfatal MI, respectively (Figure 9). By contrast,
early randomized trials (before the establishment of
current standards for secondary prevention) demon-
strated reduced rates of death, MI, and ACS with
CABG compared with MT in patients with ischemia
(7,34). For example, in the MASS II study, 1-year
usage rates of aspirin (77%), statins (63%), beta-
blockers (58%), and angiotensin-converting enzyme
inhibitors (27%) were substantially less than in
recent strategy trials (74).
Recent randomized trials with greater use of
secondary prevention measures have not shown a
reduction in death or MI after PCI or CABG in patients
with documented ischemia. In a COURAGE trial
analysis of 1,381 patients, including 468 with at least
moderate ischemia on site-interpreted SPECT studies,
PCI was not associated with a reduction in the 5-year
rate of death or MI (48) (Figure 7). Similarly, in a
separate COURAGE substudy of 621 patients with core
laboratory–interpreted SPECT data, ischemic burden
at baseline did not predict cardiovascular events,
nor did it identify a subgroup with an improvement
in prognosis after PCI (65). Although the extent ofatherosclerosis was associated with the composite
endpoint of death, MI, or ACS in this study (Figure 8),
there was no beneﬁt from PCI across the spectrum of
disease. In the BARI 2D SPECT substudy, a greater
extent of ischemia 1 year after randomization did not
predict reduced death or cardiovascular events from
revascularization (66). In the STICH trial, inducible
ischemia did not identify patients with beneﬁt from
CABG compared with MT in patients with reduced
LVEF (68). In the FAME-2 trial, FFR-guided PCI did
not signiﬁcantly reduce the 2-year risk of death or MI
compared with MT (52). FAME-2 reported an increase
in periprocedural MI (deﬁned by stringent criteria
that required $10 creatine kinase-myocardial band
[CK-MB] elevation or new Q waves with $5-fold
CK-MB elevation), but a reduction in spontaneous
MI with PCI compared with GDMT between 8 days
and 2 years. In light of recent evidence that prolonged
dual antiplatelet therapy (which is more likely to be
used after PCI than MT) reduces spontaneous MI and
the composite rate of cardiovascular death, MI, and
stroke (75,76), the extent to which late beneﬁts of PCI
in FAME-2 and reductions of death and MI in some
meta-analyses with PCI (53) are attributable to dual
antiplatelet therapy, rather than revascularization,
is uncertain.
The impact of revascularization on angina-related
QoL has more evidence to support its practice,
although its effects are time-limited, and intensive
MT results in a high proportion of patients becoming
angina-free. In the COURAGE trial, using the Seattle
Angina Questionnaire, patients randomized to PCI
reported greater freedom from angina for 24 months
after the procedure (35). In the BARI 2D study,
greater freedom from angina with revascularization
compared with intensive MT lasted beyond 1 year
only in the CABG stratum (36). Finally, a report from
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patients with SIHD found no difference in angina re-
lief between the 2 approaches at the end of study
follow-up (RR: 1.10; 95% CI: 0.97 to 1.26) (40). The
incremental beneﬁt of PCI observed in older trials
(OR: 3.38; 95% CI: 1.89 to 6.04) was substantially less
or absent in recent trials (OR: 1.13; 95% CI: 0.76 to
1.68), possibly due to greater use of evidence-based
therapies. It should also be recognized that a chal-
lenge in the assessment of QoL in all of these trials
is the placebo effect, given the absence of sham
PCI/CABG procedures in the comparator groups.
COST-EFFECTIVENESS AND INFORMED CONSENT. The
cost-effectiveness of routine revascularization in
SIHD must be considered. If revascularization does
not reduce cardiovascular death or MI when added
to GDMT, it is difﬁcult to justify the cost of revascu-
larization for asymptomatic patients or those with
mild symptoms who have not had a trial of anti-
anginal therapy. Furthermore, if revascularization
improves QoL (but does not reduce death or MI),
patients and payers should understand what it
costs to buy a period of freedom from angina.
In the COURAGE trial, the addition of PCI to OMT
was not cost-effective (77). The added cost of PCI
was approximately $10,000, without signiﬁcant gain
in life-years or quality-adjusted life-years (QALYs).
The incremental cost-effectiveness ratio varied from
just over $168,000 to just under $300,000 per life-
year or QALY gained with PCI. In the BARI 2D study,
cost-effectiveness also favored MT over prompt
revascularization (78). Lifetime projections of cost-
effectiveness found MT to be cost-effective ($600
per life-year added) compared with PCI, but sug-
gested that CABG may be cost-effective ($47,000
per life-year added). In the FAME-2 trial, the incre-
mental cost-effectiveness ratio of PCI was $36,000
per QALY (79), and the authors concluded that PCI
was economically attractive compared with the best
available MT. However, this analysis was limited,
because 12-month QoL data was available for only 11%
of patients in the economic substudy.
In the era of patient-centered care, patients should
be educated regarding the potential risks and beneﬁts
of undergoing versus not undergoing revasculariza-
tion. Interviews of patients suggest that they are not
truly knowledgeable after receiving “informed con-
sent” for elective PCI. Rothberg et al. (80) found that
most patients believe elective PCI will prevent death
or MI. Better informed patients are less likely to
choose angiography and possible PCI (81). Decision
support tools are needed to assess procedural risk
and educate patients about the probability of death
or MI and improved QoL with or without PCI orCABG. Part of the challenge is that providers are not
skilled at explaining risks in probabilistic terms to
patients. Providers need training to accurately and
effectively communicate potential risks and beneﬁts
to patients.
ANALYSIS, DATA GAPS, AND
FUTURE DIRECTIONS
ACKNOWLEDGING EQUIPOISE. Credible observa-
tional data support the position that ischemia is a
predictor of adverse events, or alternatively, the
position that systemic inﬂammation and throm-
bosis of vulnerable plaques (either with or without
ischemia) are responsible for most cases of cardio-
vascular death, MI, and ACS (82,83). The optimal
approach to patients with SIHD remains unsettled
because all prior randomized trials, either by design
or execution, have limitations. Indeed, varying
COURAGE nuclear substudy results can be used to
support either routine revascularization or a more
conservative approach. Similarly, the case can be
made from large-scale observational studies and ran-
domized trial substudy data that either initial strategy
is appropriate. The strengths and limitations of ran-
domized trials versus observational studies must be
weighed. For example, death and MI was not reduced
in 2,287 patients with SIHD randomized to PCI plus
OMT versus OMT in the randomized COURAGE trial
(8), but revascularization (PCI or CABG) compared
with MT was associated with reduced death and MI
among 9,676 propensity-matched “real-world” pa-
tients meeting COURAGE eligibility criteria (18). Are
these discordant results explained by residual con-
founding in the observational study analysis (e.g.,
factors contributing to patient unsuitability for
revascularization after cardiac catheterization), by the
inclusion of a higher-risk population, revasculariza-
tion by CABG, as well as PCI, and more endpoints
yielding greater power to elicit differences between
the groups, or by better MT in the clinical trial setting?
Frequent crossovers in strategy trials, although ar-
guably representing an essential aspect of each
approach, reduce power to demonstrate differences.
For example, in the STICH trial, CABG reduced mor-
tality in both the per-protocol and crossover patient
populations (although whether ischemia was a
modulating inﬂuence in these cohorts was not re-
ported) (84). It should also be acknowledged that the
risk proﬁle of patients with SIHD may vary greatly,
independent of the degree of ischemia, and that
optimal tools for risk stratiﬁcation are lacking.
When data are conﬂicting or individual trials are
underpowered, meta-analysis is often relied upon to
TABLE 2 Current Guideline Indications for Revascularization in SIHD
To Improve Survival To Improve Symptoms
Class of
Recommendation
Level of
Evidence
Class of
Recommendation
Level of
Evidence
2012/2014 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guidelines (10,11)
Left main disease
CABG I B — —
PCI IIa, IIb or III* B or C* — —
3-vessel disease
CABG I B — —
PCI IIb B — —
2-vessel disease with PLAD disease
CABG I B — —
PCI IIb B — —
2-vessel disease without PLAD disease
CABG IIa B — —
CABG IIb C — —
PCI IIb B — —
1-vessel disease with PLAD disease
CABG IIa B — —
PCI IIb B — —
1-vessel disease without PLAD disease
CABG III B — —
PCI III B — —
Left ventricular dysfunction
CABG IIa or IIb† B — —
CABG IIb B — —
PCI —‡ —
Unacceptable angina despite GDMT‡
PCI or CABG — — I A
PCI — — IIa§ C
CABG — — IIb§ C
Unacceptable angina with GDMT noncompliance or side effects,
or patient preferencek
PCI or CABG — — IIa C
2013/2014 ESC/EACTS guidelines (12,13)
Left main disease I A I A
Proximal LAD disease I A I A
Multivessel disease with LVEF <40% I B IIa B
Large area of ischemia (>10% LV) I B I B
Single remaining vessel I C I A
Limiting symptoms or symptoms not responsive/intolerant to GDMT — — I A
Heart failure with >10% ischemia/viability IIb B IIa B
No limiting symptoms with GDMT and with none of the above
or with FFR $0.80
III A III C
*Varies according to associated clinical conditions and anatomic complexity. †IIa for LVEF 35% to 50%; IIb for LVEF <35% without left main disease. ‡Insufﬁcient data for a
recommendation. §In patients with prior CABG. kIn patients with signiﬁcant anatomic (>50% left main or >70% non–left main disease) or physiological (FFR <0.80) coronary
artery stenoses.
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS ¼ American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines/American College of
Physicians/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of
Thoracic Surgeons; ESC ¼ European Society of Cardiology; EACTS ¼ European Association for Cardio-Thoracic Surgery; FFR ¼ fractional ﬂow reserve; LAD ¼ left anterior
descending coronary artery; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; PLAD ¼ proximal left anterior descending artery; other abbreviations as in Table 1.
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95provide a consensus direction. However, the results of
meta-analyses may vary tremendously, depending on
the studies selected for inclusion. For example, some
meta-analyses included patients with recent MI;
others did not. Meta-analyses share the limitations of
their component trials, and have other drawbacks thatmay not be immediately obvious. For example, in the
100-trial network meta-analysis of revascularization
versus MT (47), only 15 trials had a MT arm that re-
ported all-cause mortality. Most of the conclusions
from this study were thus drawn from indirect com-
parisons across studies, and should be considered
CENTRAL ILLUSTRATION Ischemia Revascularization Equipoise:
The ISCHEMIA Trial Design
+
Patients with stable ischemic heart disease (SIHD) and moderate or severe ischemia
Refer patients with eGFR <30 or on dialysis to ISCHEMIA-CKD trial
Blinded coronary CT angiogram* to exclude patients
Randomize patients into ISCHEMIA trial approaches
After average 3-year follow-up, compare rates of cardiovascular death
and myocardial infarction. Also compare quality of life (secondary endpoint)
(Based on the present level of evidence
can be made for either initial approach)
Optimal medical therapy (OMT) 
with cardiac catheterization (Cath)
reserved for failure of OMT
CONSERVATIVE
OMT
+
Cath
+
Optimal revascularization
INVASIVE
Stone, G.W. et al. J Am Coll Cardiol. 2016; 67(1):81–99.
CCTA may not be performed in participants with estimated glomerular ﬁltration rate
<60 ml/min. Participants in whom CCTA shows signiﬁcant left main disease ($50%
stenosis) or no obstructive disease are excluded. CCTA results are otherwise kept blinded.
Cath ¼ catheterization; CCTA ¼ coronary computed tomographic angiography; CKD ¼
chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration rate; OMT ¼ optimal
medical therapy; SIHD ¼ stable ischemic heart disease.
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96hypothesis-generating. Moreover, patient-level data
were not available, and thus comparisons were unad-
justed. Numerous confounders were likely present,
which varied between studies, including differences in
baseline patient and lesion characteristics, and the type
of and adherence to GDMT and other pharmacother-
apies. Endpoint deﬁnitions, such as periprocedural MI,
varied between studies. Subgroup analysis was not
possible, and outcomes according to the extent of CAD
and ischemia are undetermined. In addition, these
studies were performed over several decades, and
controlling for evolution in general medical practice is
not possible. Indeed, many of these studies are of
questionable relevance to contemporary practice, given
advances in GDMT and revascularization techniques
and devices. These and other factors likely explain why
many of the 16 meta-analyses described in the present
report reached diametrically opposite conclusions.Beyond death and MI, the extent to which revas-
cularization incrementally improves QoL may also
be debated, and the frequency and importance of
revascularization-related complications, as well as
the impact of drug-related side effects on QoL and
adherence must be considered. And although both
emphasize the central role of GDMT in all patients
with SIHD, current U.S. and European guidelines
differ regarding the strength of the evidence for
revascularization in SIHD, and the relative weight
that should be accorded to anatomy versus ischemia
when considering whether revascularization is useful
(10–13) (Table 2). Reasonable physicians may variably
evaluate the strength of the evidence presented
herein; thus, a lucid argument can be made for either
management approach, emphasizing the importance
of shared decision making between the treating
cardiologist, the referring physician, and the patient.
Thus, despite strongly held individual beliefs, the
overall balance of data supporting each approach
reﬂects a state of “community equipoise” (85).
Exemplifying this equipoise, only 35% to 65% of
SIHD patients with documented moderate or severe
ischemia undergo cardiac catheterization within
90 days (86,87).
An adequately powered, randomized trial of
contemporary conservative versus invasive ap-
proaches is greatly needed to provide guidance for
the optimal approach in patients with SIHD, moderate
or severe ischemia, and symptoms that can be
controlled with MT. Despite frequently held fervent
beliefs favoring either early revascularization or
initial GDMT in SIHD, 80% of 499 cardiologists sur-
veyed stated that they would enroll their patients
with stable anginal symptoms, >10% myocardial
ischemia, and normal LVEF in a randomized trial with
a 50% chance of being conservatively managed
without cardiac catheterization, provided their pa-
tients did not have very high-risk features on stress
imaging (88). Following this positive response, the
ISCHEMIA trial was formulated.
THE ISCHEMIA TRIAL. The primary aim of the
ISCHEMIA trial (NCT01471522) is to determine
whether an initial invasive strategy of cardiac cathe-
terization and optimal revascularization (with PCI or
CABG, as determined by the local heart team) plus
OMT will reduce the primary composite endpoint of
cardiovascular death or nonfatal MI in SIHD patients
with moderate or severe ischemia and medically
controllable or absent symptoms, as compared with
an initial conservative strategy of OMT alone,
with catheterization reserved for failure of OMT
(Central Illustration). The major secondary endpoint is
angina-related QoL. Other important secondary
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97endpoints are health resource utilization, costs, and
cost-effectiveness. The National Heart, Lung, and
Blood Institute is sponsoring the trial, with oversight
by a National Heart, Lung, and Blood Institute–
appointed independent data and safety monitoring
board. In addition to the main trial, patients with
advanced chronic kidney disease (estimated glomer-
ular ﬁltration rate <30 ml/min or on dialysis) are
randomized in a parallel substudy. Blinded CCTA is
performed before randomization in participants with
normal renal function to exclude those with signiﬁ-
cant left main disease and no obstructive CAD.
Enrollment began in late 2012 and is projected to end
in 2017. Average follow-up will be approximately
3 years. There are currently w300 participating sites
in more than 30 countries. The ISCHEMIA study thus
aims to address limitations of previous strategy
trials by: 1) enrolling patients before catheterization,
so that anatomically high-risk patients are not
excluded; 2) enrolling a higher-risk group with at
least moderate ischemia; 3) minimizing crossovers; 4)
using contemporary DES and physiologically guided
decision making (FFR) to achieve complete ischemic
(rather than anatomic) revascularization; and 5) being
adequately powered to demonstrate whether routinerevascularization reduces cardiovascular death or
nonfatal MI in patients with SIHD and at least
moderate ischemia.
The results of the ISCHEMIA trial will have
important implications regarding global guidelines
for performance and reimbursement of revasculari-
zation procedures in patients with SIHD. To date,
over 2,000 patients have been randomized, with no
safety concerns expressed by the data and safety
monitoring board. Given the clear state of community
equipoise that exists regarding how best to manage
patients with SIHD, it is our hope that primary care
providers, cardiologists, and cardiac surgeons around
the world will enthusiastically support enrollment of
their patients into the ISCHEMIA trial so that we
may provide much needed prospective evidence to
inform the optimal management of patients with
SIHD, substantial myocardial ischemia, and angina
symptoms that are controlled or absent.
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